Werewolf Therapeutics GAAP EPS of -$0.38 beats by $0.07 Nov. 08, 2024 2:25 AM ET By: Manshi Mamtora , CFA [Seeking Alpha]
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting